Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeu...( CORAL GABLES Fla. July 29 /- Stie...),Health

CORAL GABLES, Fla., July 29 /PRNewswire/ -- Stiefel Laboratories, Inc. ("Stiefel Laboratories"), the world's largest independent pharmaceutical company specializing in dermatology, announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act") has expired, for its proposed acquisition of Barrier Therapeutics, Inc. ("Barrier Therapeutics") (Nasdaq: BTRX).

As previously announced, Stiefel Laboratories and Bengal Acquisition Inc., a direct wholly-owned subsidiary of Stiefel Laboratories, signed a definitive merger agreement with Barrier Therapeutics to acquire Barrier Therapeutics through a two-step transaction, a tender offer followed by a merger of Bengal Acquisition Inc. with and into Barrier Therapeutics. The transaction was approved by the board of directors of Barrier Therapeutics. Stiefel Laboratories is accomplishing the acquisition of Barrier Therapeutics through a tender offer, which commenced on July 8, 2008 and is scheduled to expire at 12:00 midnight, New York City time, on August 4, 2008, unless, subject to the terms of the merger agreement, the tender offer is extended. The tender offer is being conducted on the terms and subject to the conditions described in the Offer to Purchase, dated July 8, 2008, and the related Letter of Transmittal, which have been filed as part of Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission on July 8, 2008.

Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the tender offer and the proposed merger of Barrier Therapeutics into Bengal Acquisition Inc. No other governmental regulatory approvals are necessary for th
'/>"/>